Advertisements


Aimmune jumps 9% to $23.95 after FDA posts briefing docs for panel meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

FDA posts briefing docs for Aimmune panel, brings up allergic reactions

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

Trevena sinks 46% to $1.62 after FDA posts briefing docs ahead of panel

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 9th, 2018

Karyopharm drops 40% after FDA posts Selinexor meeting briefing docs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 22nd, 2019

Aimmune panel meeting holds "three key positives" for DBV, says Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 16th, 2019

Aimmune"s stock halted as FDA panel"s decision awaited on peanut allergy treatment

Aimmune Therapeutics Inc.'s stock has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is meeting a.....»»

Category: topSource: marketwatchSep 13th, 2019

Piper says FDA briefing docs remove key underpinning of Aimmune bear thesis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

Aimmune briefing docs look "pretty benign," says Stifel

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

Biotech Stock On The Radar: Aimmune Awaits Adcom Test

Aimmune Therapeutics Inc (NASDAQ: AIMT) shares have been on an extended downtrend since the start of 2018. This thinly traded, small-cap biotech is on the radar ahead of a key FDA panel meeting scheduled for Friday, Sept. 13. read more.....»»

Category: blogSource: benzingaSep 10th, 2019

FDA posts briefing ahead of meeting to discuss sNDA for Gilead"s Descovy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 5th, 2019

FDA posts briefing documents for advisory panel on breast implants

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 21st, 2019

AcelRx briefing docs bode well for positive panel, says H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 10th, 2018

Peninsula drug company takes big step toward peanut allergy drug approval

Aimmune Therapeutics Inc.'s quest to sell the first biologic drug to treat peanut allergies won a regulatory advisory committee's blessing Friday, moving the company closer to Food and Drug Administration approval. The action by the nine-member panel do.....»»

Category: topSource: bizjournalsSep 16th, 2019

H.C. Wainwright reiterates Buy on DBV Technologies after Aimmune panel

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 16th, 2019

Aimmune price target raised to $30 after "positive" FDA panel at Stifel

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 16th, 2019

DBV Technologies falls 2% after FDA panel votes in favor of Aimmune drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

Aimmune"s AR101 prospects derisked by FDA panel decision, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

FDA panel votes 8-1 saying Aimmune peanut allergy drug Palforzia is safe

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

FDA panel votes 7-2 saying Aimmune"s peanut allergy drug Palforzia works

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2019

Aimmune jumps as FDA materials seen as good sign for peanut allergy treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019

FDA to ask panel if Aimmune peanut allergy treatment data support approval

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 11th, 2019